Menu
Search
|

Menu

Close
X

Kamada Ltd KMDA.OQ (NASDAQ Stock Exchange Global Select Market)

5.15 USD
-0.10 (-1.90%)
As of 3:59 PM EST
chart
Previous Close 5.25
Open 5.20
Volume 1,858
3m Avg Volume 9,881
Today’s High 5.25
Today’s Low 5.15
52 Week High 8.55
52 Week Low 3.75
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 3 analysts

KEY STATS

Revenue
No Data Available
FY
-
FY
-
FY
-
FY
-
EPS
No Data Available
FY
-
FY
-
FY
-
FY
-

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
35.76
Price to Sales (TTM)
vs sector
--
8.59
Price to Book (MRQ)
vs sector
--
5.23
Price to Cash Flow (TTM)
vs sector
--
26.13
Total Debt to Equity (MRQ)
vs sector
--
15.32
LT Debt to Equity (MRQ)
vs sector
--
11.95
Return on Investment (TTM)
vs sector
--
13.59
Return on Equity (TTM)
vs sector
--
15.20

EXECUTIVE LEADERSHIP

Leon Recanati
Chairman of the Board, Since 2013
Salary: --
Bonus: --
Amir London
Chief Executive Officer, Since 2015
Salary: --
Bonus: --
David Tsur
Deputy Chairman of the Board, Since 2015
Salary: 804,000.00₪
Bonus: 763,000.00₪
Chaime Orlev
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Ruth Wolfson
Senior Vice President - Scientific Affairs, Since 2015
Salary: 402,000.00₪
Bonus: 52,000.00₪

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

2 Holtzman St., Science Park
REHOVOT     7670402

Phone: +9728.9406472

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.

SPONSORED STORIES